Samsara Inc vs Vaxcyte Inc. Common Stock — how do they compare? Samsara Inc trades at $40.5 (market cap $24.17B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Samsara Inc is far larger — about 2.3× Vaxcyte Inc. Common Stock's market cap, and Samsara Inc is more actively traded (3,228,585 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| IOT | PCVX | |
|---|---|---|
Market Cap | $24.17B | $10.51B |
Volume | 3,228,585 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $45.22 | $73.82 |
52-Week Low | $24.25 | $40.32 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $23.41B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
Samsara Inc. (IOT) trades at $41.27, down 0.84% today, with a bullish technical signal from moving averages and a consensus analyst price target of $51.15. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.20 versus $0.16 expected, and revenue growth of 30% year-over-year. Recent news highlights partnerships and product launches, including the Samsara MCP for AI integration and a rewards program for drivers.
The outlook is positive due to robust revenue growth, expanding large-customer base, and analyst optimism, but risks include high valuation multiples (P/E of 275.13) and cash flow pressures. Investment opportunity lies in continued execution and market share gains, while investors should monitor margin sustainability and competitive dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →